PATTERN OF PEDIATRIC DERMATOSES IN TERTIARY CARE HOSPITAL, GOVERNMENT MEDICAL COLLEGE, KADAPA

Dr Sirisha N L

Abstract


Background: The prevalence of pediatric dermatoses varies world wide. Pediatric dermatoses has to be studied separately as there are important differences in clinical presentation, management and prognosis  from that of an adult.

Aims and Objectives: To study clinical and etiological presentation of pediatric dermatoses in tertiary care hospital, Kadapa.

Materials and Methods: This is a prospective study  carried out over a period of 1 year , from April 2017 to May 2018 .cases upto  the age of 15 years attending the OPD of Government Medical college, Kadapa, Andhra Pradesh were selected for the study. All patients were divided into 4 study groups:<1month, 1month to 1 year, >1year to 7years and 8 to 15 years.

Results : There were 632 boys and 568 girls in a total of 1200 study population. Most common dermatoses in neonates were transient(35.58%), followed by dermatitis(24.54%) and infectious diseases(21.47%). Infectious diseases were the common presentation(54.58%) followed by dermatitis(18.32%), disorders of appendages(6.75%) and papulosqauamous diseases (6.36%) in the study population of 1 month to 15 years age group of children.

Conclusion :Due to varied presentation and burden of pediatric dermatoses there is a need to emphasize on training for dermatologists in pediatric subspeciality.


Full Text:

PDF

References


Roozbeh J, Sharifian M, Hosseini H, Sagheb MM, Behzadi S, Raeisjalali GA, et al. Senior- Loken syndrome in an Iranian family. Saudi J Kidney Dis Transpl. 2010;21(4):735–37.

Senior-Loken syndrome. Genetic and Rare Diseases Information Center (GARD). Last Update 4/13/2015. https://rarediseases.info.nih.gov/gard/322/senior-loken-syndrome/Resources/1. Accessed May 18, 2016.

Lewis RA. Løken-Senior Syndrome. In: The NORD Guide to Rare Disorders, Philadelphia: Lippincott, Williams, and Wilkins, 2003:692-3.

Gattone VH, 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–6.


Refbacks

  • There are currently no refbacks.